Fu-Kuen Lin (Chinese: 林福坤; born 1941 in Keelung, Taiwan) is a Taiwanese mycological physiologist, nephrologist and hematologist.
That year, he moved to the United States to study fungi physiology under Professor David Gottlieb at the University of Illinois at Urbana-Champaign.
He was involved with Amgen's recombinant human erythropoietin (EPO) project from the start, and was soon leading the team, which was developing EPO based on a small sample of the hormone that had been isolated by a team led by Eugene Goldwasser at the University of Chicago.
[1] In 1983 his team successfully established the gene coding for it[2] and recombinant human erythropoietin was approved by the US FDA in June 1989[3] with the generic name epoetin alpha, tradename Epogen.
His primary research interests were in the fields of hematology, hypertension, immune regulation and fungi physiology.